A Patient-Centered Approach to Refractory Overactive Bladder and Barriers to Third-Line Therapy

Overactive BladderUrinary Tract Infections (UTI)

Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes

J Pediatr Urol.

Ingham J, Angotti R, Lewis M, Goyal A

doi: 10.1016/j.jpurol.2018.08.007.

Overactive Bladder

Patient-targeted websites on overactive bladder: What are our patients reading?

Neurourol Urodyn.

Clancy AA, Hickling D, Didomizio L, Sanaee M, Shehata F, Zee R, Khalil H

doi: 10.1002/nau.23359.

Overactive Bladder

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Neurourol Urodyn.

Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C

doi: 10.1002/nau.23919.

Overactive Bladder

Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial

JAMA Intern Med.

Burgio KL, Kraus SR, Johnson TM 2nd, Markland AD, Vaughan CP, Li P, Redden DT, Goode PS

doi: 10.1001/jamainternmed.2019.6398.

Overactive Bladder

Initial clinical experience with selective bladder denervation for refractory overactive bladder

Neurourol Urodyn.

Tu LM, De Wachter S, Robert M, Dmochowski RR, Miller LE, Everaert K

doi: 10.1002/nau.23881.

Overactive Bladder

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Health Qual Life Outcomes.

Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR

doi: 10.1186/s12955-018-0892-0.

Overactive Bladder

Detection and quantification of overactive bladder activity in patients: Can we make it better and automatic?

Neurourol Urodyn.

Niederhauser T, Gafner ES, Cantieni T, Grämiger M, Haeberlin A, Obrist D, Burkhard F, Clavica F

doi: 10.1002/nau.23357.

Overactive Bladder

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

Eur Urol.

Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, Stoelzel M, Maanen RV, Siddiqui E

doi: 10.1016/j.eururo.2019.07.010.

Overactive Bladder

Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience

Urologia.

Tamburro FR, Castellan P, Neri F, Berardinelli F, Bada M, Sountoulides P, Giuliani N, Finazzi Agrò E, Schips L, Cindolo L

doi: 10.1177/0391560318759258.

Related content

Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes

Patient-targeted websites on overactive bladder: What are our patients reading?

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial

Initial clinical experience with selective bladder denervation for refractory overactive bladder

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Detection and quantification of overactive bladder activity in patients: Can we make it better and automatic?

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience